However, therapy resistance to TKIs leads to loss of molecular remission in about 25% of CML patients being partially due to BCR::ABL1 kinase mutations, while for the remaining cases, various other mechanisms are discussed. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.